Meeting
2021 Genitourinary Cancers Symposium
PROSPER subgroup analysis by age and region: Overall survival and safety in men with nonmetastatic castration-resistant prostate cancer receiving androgen deprivation therapy plus enzalutamide.
Presenter
Ugo De Giorgi, MD, PhD
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Advanced Disease
Track
Prostate Cancer - Advanced
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02003924
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 84)
DOI
10.1200/JCO.2021.39.6_suppl.84
Abstract #
84
Poster Bd #
Online Only
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2023 ASCO Genitourinary Cancers Symposium
A study to determine enzalutamide long term safety and efficacy for men with castration-resistant prostate cancer: A multicenter, prospective DELC study.
Speaker: Koji Hatano, MD, PhD
Speaker: Panel Discussion
Speaker: Shirish M. Gadgeel, MD
Videos & Slides
2021 Genitourinary Cancers Symposium
Overall survival (OS) and metastasis-free survival (MFS) by depth of prostate-specific antigen (PSA) decline in the phase III PROSPER trial of men with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide (ENZA).
Speaker: Maha H. A. Hussain, MD, FACP, FASCO